These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37099842)

  • 1. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.
    Méndez C; Peñaloza HF; Schultz BM; Piña-Iturbe A; Ríos M; Moreno-Tapia D; Pereira-Sánchez P; Leighton D; Orellana C; Covarrubias C; Gálvez NMS; Soto JA; Duarte LF; Rivera-Pérez D; Vázquez Y; Cabrera A; Bustos S; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Melo-González F; Bueno SM; Kalergis AM
    EBioMedicine; 2023 May; 91():104563. PubMed ID: 37099842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
    Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; ; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM
    mBio; 2022 Dec; 13(6):e0131122. PubMed ID: 36383021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
    Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
    Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
    Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
    Gálvez NMS; Pacheco GA; Schultz BM; Melo-González F; Soto JA; Duarte LF; González LA; Rivera-Pérez D; Ríos M; Berrios RV; Vázquez Y; Moreno-Tapia D; Vallejos OP; Andrade CA; Hoppe-Elsholz G; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; Johnson M; Goldblatt D; González PA; Abarca K; Bueno SM; Kalergis AM
    Elife; 2022 Oct; 11():. PubMed ID: 36226829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.
    Hu J; Liu Y; Liu S; Shu Q; Yang X; Chu K; Qiao Y; Hu Y; Wang K; Pan H
    Front Immunol; 2023; 14():1241153. PubMed ID: 37799724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.
    Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S
    Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NM; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Vallejos OP; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    medRxiv; 2022 Feb; ():. PubMed ID: 35441179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study.
    Kuloğlu ZE; El R; Guney-Esken G; Tok Y; Talay ZG; Barlas T; Kuskucu MA; Albayrak Ö; Doğan Ö; Yavuz SŞ; Midilli K; Ergönül Ö; Can F
    Allergy; 2022 Aug; 77(8):2459-2467. PubMed ID: 35437772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients.
    Chen Y; Zhao T; Chen L; Jiang G; Geng Y; Li W; Yin S; Tong X; Tao Y; Ni J; Lu Q; Ning M; Wu C
    mBio; 2024 Apr; 15(4):e0240723. PubMed ID: 38456703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.